JP2025516543A5 - - Google Patents

Info

Publication number
JP2025516543A5
JP2025516543A5 JP2024566197A JP2024566197A JP2025516543A5 JP 2025516543 A5 JP2025516543 A5 JP 2025516543A5 JP 2024566197 A JP2024566197 A JP 2024566197A JP 2024566197 A JP2024566197 A JP 2024566197A JP 2025516543 A5 JP2025516543 A5 JP 2025516543A5
Authority
JP
Japan
Prior art keywords
egfr inhibitor
combination
independently selected
combination according
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516543A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/062530 external-priority patent/WO2023217924A1/en
Publication of JP2025516543A publication Critical patent/JP2025516543A/ja
Publication of JP2025516543A5 publication Critical patent/JP2025516543A5/ja
Pending legal-status Critical Current

Links

JP2024566197A 2022-05-13 2023-05-11 がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ Pending JP2025516543A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22173211 2022-05-13
EP22173211.8 2022-05-13
EP22175302 2022-05-25
EP22175302.3 2022-05-25
PCT/EP2023/062530 WO2023217924A1 (en) 2022-05-13 2023-05-11 Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2025516543A JP2025516543A (ja) 2025-05-30
JP2025516543A5 true JP2025516543A5 (cg-RX-API-DMAC7.html) 2026-05-18

Family

ID=86558741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566197A Pending JP2025516543A (ja) 2022-05-13 2023-05-11 がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ

Country Status (9)

Country Link
US (1) US20260007678A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522113A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025516543A (cg-RX-API-DMAC7.html)
KR (1) KR20250009977A (cg-RX-API-DMAC7.html)
CN (1) CN119173253A (cg-RX-API-DMAC7.html)
AU (1) AU2023268579A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255503A1 (cg-RX-API-DMAC7.html)
TW (1) TW202408534A (cg-RX-API-DMAC7.html)
WO (1) WO2023217924A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2961187T3 (es) 2019-06-21 2024-03-08 Hoffmann La Roche Inhibidor de EGFR para el tratamiento del cáncer
CN116507328A (zh) 2020-12-01 2023-07-28 豪夫迈·罗氏有限公司 新的吲唑衍生物
IL303064A (en) 2020-12-01 2023-07-01 Hoffmann La Roche NEW INDAZOLE ACETYLENE DERIVATIVES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2961187T3 (es) * 2019-06-21 2024-03-08 Hoffmann La Roche Inhibidor de EGFR para el tratamiento del cáncer
CN116507328A (zh) * 2020-12-01 2023-07-28 豪夫迈·罗氏有限公司 新的吲唑衍生物
IL303064A (en) * 2020-12-01 2023-07-01 Hoffmann La Roche NEW INDAZOLE ACETYLENE DERIVATIVES
JP7798887B2 (ja) * 2020-12-01 2026-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体

Similar Documents

Publication Publication Date Title
ES2985528T3 (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades
US20220241261A1 (en) Combinations of inhibitors of irak4 with inhibitors of btk
EP2101759B1 (en) Methods of using mek inhibitors
JP2025508703A5 (cg-RX-API-DMAC7.html)
JP7592689B2 (ja) Ｓｔｉｎｇアゴニストとしての大環状化合物並びにその方法及び使用
JP6537527B2 (ja) Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置
WO2024229447A1 (en) Pyrido[4,3-d]pyrimidine derivatives as mutant kras g12c inhibitors for the treatment of cancer
RU2472509C2 (ru) Способ лечения артрита
JP2020510015A5 (cg-RX-API-DMAC7.html)
JP2021519775A5 (cg-RX-API-DMAC7.html)
JP2012524053A5 (cg-RX-API-DMAC7.html)
JP2020510010A5 (cg-RX-API-DMAC7.html)
JP2005538099A5 (cg-RX-API-DMAC7.html)
IL279800B1 (en) Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use
JP2013520420A5 (cg-RX-API-DMAC7.html)
JP2022513409A5 (cg-RX-API-DMAC7.html)
JP2023550902A5 (cg-RX-API-DMAC7.html)
JP2013522372A5 (cg-RX-API-DMAC7.html)
JP2012508239A (ja) Ｐ７０ｓ６キナーゼ阻害剤およびｍｔｏｒ阻害剤の併用療法
JP2025510910A5 (cg-RX-API-DMAC7.html)
JP2024516430A5 (cg-RX-API-DMAC7.html)
JP2009500366A5 (cg-RX-API-DMAC7.html)
WO2018186366A1 (ja) 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
JP2023522693A5 (cg-RX-API-DMAC7.html)
RU2024137254A (ru) Комбинация аллостерических и ортостерических ингибиторов egfr для лечения рака